A groundbreaking international trial is now underway to evaluate an mRNA vaccine targeting norovirus, a notorious pathogen responsible for the seasonal “winter vomiting” illness. The initiative aims to alleviate the significant health burden associated with the virus, particularly in light of a recently identified strain that is driving a surge in cases globally, notably in England.
Patrick Moore from the National Institute for Health and Care Research, who is overseeing the UK segment of the trial, stated, “Unfortunately, one of the strains which is most prevalent isn’t included in that jab.” This highlights the urgency of the ongoing research as health officials grapple with rising infection rates.
